TU + ENG
Alternative Name: Testosterone undecanoate (TU) + etonogestrel (ENG)
Description: The tested product was a combination of an etonogestrel (ENG) implant combined with testosterone undecanoate (TU) injections for male contraception.
Product Details
User: Male
Hormonal: Yes
Delivery Method: Injectable, Subdermal
Duration Type: Short-acting
Active Pharmaceutical Ingredient (API): - testosterone undecanoate
- etonogestrel
- testosterone undecanoate
- etonogestrel
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: Organon
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Phase II
Active Development: No
Status Details: - A Phase IIb, placebo-controlled trial investigating the efficacy, safety and pharmacokinetics of the product was completed in 2006.
- A Phase IIb, placebo-controlled trial investigating the efficacy, safety and pharmacokinetics of the product was completed in 2006.
Additional Information
References: Mommers E, et al. (2008) Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 93(7): 2572-80.
Liu PY, McLachlan RI. (2008) Male hormonal contraception: so near and yet so far. J Clin Endocrinol Metab. 93(7): 2474-6.
Mommers E, et al. (2008) Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 93(7): 2572-80.
Liu PY, McLachlan RI. (2008) Male hormonal contraception: so near and yet so far. J Clin Endocrinol Metab. 93(7): 2474-6.
Footnotes: - In 2007, Schering-Plough Corporation acquired Organon and in 2009, merged with Merck & Co.
- In 2007, Schering-Plough Corporation acquired Organon and in 2009, merged with Merck & Co.